[Anhidrosis during long-term hydroxyurea therapy in a patient with chronic myelogenous leukemia].
A 62-year-old man was diagnosed as being in the chronic phase of chronic myelogenous leukemia (CML) in 1990, and subsequently treated with hydroxyurea (HU). The total HU dose administered reached 2,929 g (average, 1.44 g/day). In December 1995, the patient was admitted to our hospital for control of the CML. Following HU therapy, he often experienced high fever (38-39 degrees C) due to infection or blastosis, and at that time his skin showed marked pigmentation, dryness and scaling with itching and anhidrosis. A skin biopsy sample from the left scapula showed atrophic change of the skin and epidermal tissues with fibrotic changes and damage to the subcutaneous glands. This was strongly suspected to have been caused by the continuous HU administration, and the anhidrosis and dryness was considered to have contributed to the patient's high body temperature. Frequent cooling of the patient's body was effective.
Takagi
K
K
Division of Internal Medicine, Hayashi Hospital.
Nakamura
T
T
Misaki
H
H
Ueda
T
T
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects*; D007007:Hypohidrosis / Q000209:etiology* / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000187:drug effects / Q000473:pathology*; D013995:Time
D000970:Antineoplastic Agents; D006918:Hydroxyurea